Half Yearly Report and Accounts
Released
Released
Announcement PDF
Resonance Health Limited
Appendix 4D
Half-year report
1. Company details
Name of entity:
ABN:
Reporting period:
Previous period:
Resonance Health Limited
96 006 762 492
For the half-year ended 31 December 2024
For the half-year ended 31 December 2023
2. Results for announcement to the market
$
Revenues from ordinary activities
up
60% to
5,210,477
Loss from ordinary activities after tax attributable to the owners of
Resonance Health Limited
up
86% to
(1,036,192)
Loss for the half-year attributable to the owners of Resonance Health
Limited
up
86% to
(1,036,192)
Dividends
There were no dividends paid, recommended or declared during the current financial period.
Comments
The loss for the Group after providing for income tax amounted to $1,036,192 (31 December 2023: $557,552). The FY24
half year result included an income tax benefit of $473,286 which was the net difference between the Group’s Research
and Development (R&D) tax incentive refund for R&D performed in the FY2024 year totaling $786,417 and the total
amount of income taxation payable by the Group given its FY2024 financial performance totaling $313,131.
3. Net tangible assets
31 December
2024
Cents
Net current tangible assets per ordinary security
Net tangible assets per ordinary security
4. Control gained over entities
Not applicable.
5. Loss of control over entities
Not applicable.
6. Dividends
Current period
There were no dividends paid, recommended or declared during the current financial period.
0.49
(0.04)
30 June
2024
Cents
0.70
0.13
Resonance Health Limited
Appendix 4D
Half-year report
Previous period
There were no dividends paid, recommended or declared during the previous financial period.
7. Audit qualification or review
Details of audit/review dispute or qualification (if any):
The financial statements were subject to a review by the auditors and the review report is attached as part of the HalfYear Financial Report.
8. Attachments
Details of attachments (if any):
The Half-Year Financial Report of Resonance Health Limited for the half-year ended 31 December 2024 is attached.
9. Signed
Signed ___________________________
Dr Martin Blake
Chairperson
Perth, Western Australia
Date: 27 February 2025
Resonance Health Limited
ABN 96 006 762 492
Half-Year Financial Report - 31 December 2024
Resonance Health Limited
Corporate directory
31 December 2024
Directors
Dr Martin Blake - Non-executive Chairman
Mr Aaron Brinkworth - Non-executive Director
Mr Mitchell Wells - Non-executive Director
Mr Simon Panton - Non-executive Director
Dr Travis Baroni - Non-executive Director
Chief Executive Officer
Mr Andrew Harrison
Company secretary
Mr Mitchell Wells
Registered office
141 Burswood Road
BURSWOOD WA 6100
T: +61 8 9286 5300
F: +61 8 9286 5399
Principal place of business
141 Burswood Road
BURSWOOD WA 6100
T: +61 8 9286 5300
F: +61 8 9286 5399
Share register
Automic Group
Level 5, 191 St Georges Terrace
Perth WA 6000
Telephone: 1300 288 664
Auditor
HLB Mann Judd
Level 4
130 Stirling Street
Perth WA 6000
Solicitors
Steinepreis Paganin
Level 14, QV1
250 St Georges Terrace
Perth WA 6000
Bankers
National Australia Bank Limited
Stock exchange listing
Resonance Health Limited shares are listed on the Australian Securities Exchange
(ASX code: RHT)
Website
www.resonancehealth.com
www.trialswest.com.au
email: info@resonancehealth.com
1
Resonance Health Limited
Contents
31 December 2024
Directors' report
Auditor's independence declaration
Condensed consolidated statement of profit or loss and other comprehensive income
Condensed consolidated statement of financial position
Condensed consolidated statement of changes in equity
Condensed consolidated statement of cash flows
Notes to the condensed financial statements
Directors' declaration
Independent auditor's review report
2
3
5
6
7
8
9
10
22
23
Resonance Health Limited
Directors' report
31 December 2024
The Directors present their report, together with the financial statements, on the consolidated entity (referred to
hereafter as the 'Group') consisting of Resonance Health Limited (referred to hereafter as the 'Company' or 'parent entity')
and the entities it controlled at the end of, or during, the half-year ended 31 December 2024.
Directors
The following persons were Directors of Resonance Health Limited during the whole of the financial half-year and up to
the date of this report, unless otherwise stated:
Dr Martin Blake
Mr Mitchell Wells
Mr Aaron Brinkworth
Mr Simon Panton
Dr Travis Baroni
Principal activities
The Group’s core business is the development and commercialisation of software-as-medical-device (‘SaMD’)
technologies and services for the quantitative analysis of radiological images in a regulated and quality-controlled
environment.
The Group’s core SaMD product is FerriScan®, a non-invasive liver analysis technology used for the assessment of iron in
the liver. Other Company SaMDs include Cardiac T2*, for the assessment of iron in the heart, and HepaFat-Scan® for the
assessment of fat in and around the liver. The Company also has several AI-assisted SaMDs including FerriSmart®,
HepaFatSmart, and LiverSmart®.
In addition to its core business, the Group operates as the Clinical Trial Research Organisation (CRO) and local sponsor in
Australia on two clinical trials for a major global pharma company’s new drug compound. The Group is overseeing aspects
of the conduct and delivery of these trials in Australia.
The Group further expanded into the clinical trial ecosystem during the previous financial year with the acquisition of
TrialsWest Pty Ltd (TrialsWest). TrialsWest is a clinical research centre that partners with some of the world’s leading
pharmaceutical and biotechnology companies to help bring new medicines and vaccines to the global community.
Specifically, TrialsWest offers site management services to the clinical trial market specializing in the delivery of clinical
trials in the community.
Review of operations
The loss for the Group after providing for income tax amounted to $1,036,192 (31 December 2023: $557,552).
The FY2024 half year result included an income tax benefit of $473,286 which was the net difference between the Group’s
Research and Development (R&D) tax incentive refund for R&D performed in the FY2024 year totaling $786,417 and the
total amount of income taxation payable by the Group given its FY2024 financial performance totaling $313,131.
Sales revenue increased by 60% to $5,210,477 (31 December 2023: $3,265,560), and Revenue and Other Income increased
by 55% to $5,268,641 (31 December 2023: $3,389,403). The higher revenues were driven by the continuation of the
clinical trial agreements with a global pharmaceutical company which contributed approximately $1.7 million in revenue
in the period and the introduction of TrialsWest into the Group which contributed approximately $1.0 million in revenue
in the period. In addition, the Group experienced increased sales volumes across its FerriScan, FerriSmart and
HepaFatSmart products in particular.
The revenue associated with the delivery of the clinical trial agreements with a global pharmaceutical company is
recognised according to the delivery of the trials rather than amounts invoiced. Total invoiced amounts in the half year
period related to these two clinical trials was $3.0 million (compared to revenue recognised of $1.7 million).
Research and development expenditure totalled $870,112 for the half-year (31 December 2023: $728,130). This
comprised capitalised development costs of $83,719 that are recognised as an intangible asset on the Condensed
Statement of Financial Position and items recognised in the Condensed Statement of Comprehensive Income, being
$273,990 amortisation expense and $512,403 research and development expense.
3
Resonance Health Limited
Directors' report
31 December 2024
Intangible assets, representing capitalised research and development expenditure, goodwill and other intangible assets,
totalled $9,693,060 at the end of the half-year (30 June 2024: $9,863,790).
The Group has $3,512,715 in cash and cash equivalents at the end of the half-year (30 June 2024: $6,854,820).
Significant changes in the state of affairs
There were no other significant changes in the state of affairs of the Group during the financial half-year.
Auditor's independence declaration
A copy of the auditor's independence declaration as required under section 307C of the Corporations Act 2001 is set out
immediately after this Directors' report.
This report is made in accordance with a resolution of Directors, pursuant to section 306(3)(a) of the Corporations Act
2001.
On behalf of the Directors
___________________________
Dr Martin Blake
Chairperson
27 February 2025
Perth, Western Australia
4
AUDITOR’S INDEPENDENCE DECLARATION
As lead auditor for the review of the consolidated financial report of Resonance Health Limited for
the half-year ended 31 December 2024, I declare that to the best of my knowledge and belief, there
have been no contraventions of:
a)
the auditor independence requirements of the Corporations Act 2001 in relation to the review;
and
b)
any applicable code of professional conduct in relation to the review.
Perth, Western Australia
27 February 2025
N G Neill
Partner
5
Resonance Health Limited
Condensed consolidated statement of profit or loss and other comprehensive income
For the half-year ended 31 December 2024
Note
Consolidated
31 Dec 2024 31 Dec 2023
$
$
Revenue
4
5,210,477
3,265,560
Other income
5
58,164
123,843
6,7
8
(215,417)
(273,990)
(142,490)
(455,663)
(1,440,359)
(2,815,433)
(512,403)
(174,269)
66,228
(155,615)
(169,094)
(489,614)
(108,612)
(134,081)
(459,770)
(354,750)
(376,034)
(1,590,342)
(531,476)
(85,263)
31,079
(97,426)
(240,280)
(1,509,478)
(557,552)
Income tax benefit
473,286
-
Loss after income tax benefit for the half-year attributable to the owners of
Resonance Health Limited
(1,036,192)
Expenses
Depreciation expense
Amortisation expense
Share-based payments
Marketing & travel
Consulting and professional services
Employee benefits expense
Research and development
Statutory and compliance
Foreign exchange gain/(loss)
Finance costs
Occupancy expenses
Other expenses
Loss before income tax benefit
Other comprehensive income for the half-year, net of tax
Total comprehensive loss for the half-year attributable to the owners of
Resonance Health Limited
-
-
(1,036,192)
(557,552)
Cents
Basic loss per share
Diluted loss per share
(557,552)
(0.23)
(0.23)
Cents
(0.12)
(0.12)
The above condensed statement of profit or loss and other comprehensive income should be read in conjunction with the
accompanying notes
6
Resonance Health Limited
Condensed consolidated statement of financial position
As at 31 December 2024
Note
Consolidated
31 Dec 2024 30 Jun 2024
$
$
Assets
Current assets
Cash and cash equivalents
Trade and other receivables
Other assets
Total current assets
3,512,715
3,208,735
315,624
7,037,074
6,854,820
2,320,442
109,980
9,285,242
550,459
527,149
9,693,060
130,600
10,901,268
522,791
492,048
9,863,790
119,096
10,997,725
17,938,342
20,282,967
1,433,098
183,314
733,796
320,000
2,050,731
85,164
4,806,103
1,270,551
171,630
373,141
320,000
11,240
4,000,000
6,146,562
400,975
2,693,333
3,094,308
351,439
2,853,333
3,204,772
Total liabilities
7,900,411
9,351,334
Net assets
10,037,931
10,931,633
Non-current assets
Property, plant and equipment
Right-of-use assets
Intangibles
Other assets
Total non-current assets
6
7
8
Total assets
Liabilities
Current liabilities
Trade and other payables
Lease liabilities
Provisions
Borrowings
Other liabilities
Deferred Consideration Payable
Total current liabilities
9
10
18
Non-current liabilities
Lease liabilities
Borrowings
Total non-current liabilities
9
Equity
Issued capital
Reserves
Accumulated losses
11
Total equity
74,452,640 74,166,888
2,493,883
2,637,145
(66,908,592) (65,872,400)
10,037,931
10,931,633
The above condensed statement of financial position should be read in conjunction with the accompanying notes
7
Resonance Health Limited
Condensed consolidated statement of changes in equity
For the half-year ended 31 December 2024
Foreign
currency
translation
reserve
$
Consolidated
Issued
capital
$
Balance at 1 July 2023
73,882,788
(270,580)
2,364,805
(66,041,702)
9,935,311
Loss after income tax benefit for the half-year
Other comprehensive income for the halfyear, net of tax
-
-
-
(557,552)
(557,552)
-
-
-
-
-
Total comprehensive loss for the half-year
-
-
-
(557,552)
(557,552)
284,100
-
-
(284,100)
459,770
-
459,770
74,166,888
(270,580)
2,540,475
(66,599,254)
9,837,529
Transactions with owners in their capacity as
owners:
Vesting of Tranche A Performance Rights
(note 17)
Share-based payments (note 17)
Balance at 31 December 2023
Foreign
currency
translation
reserve
$
Options
reserve
$
Accumulated
losses
Total equity
$
$
Consolidated
Issued
capital
$
Balance at 1 July 2024
74,166,888
(270,580)
2,907,725
(65,872,400)
10,931,633
-
-
-
(1,036,192)
(1,036,192)
-
-
-
-
-
-
-
-
(1,036,192)
(1,036,192)
285,752
-
-
(285,752)
142,490
-
142,490
74,452,640
(270,580)
2,764,463
(66,908,592)
10,037,931
Loss after income tax benefit for the halfyear
Other comprehensive income for the halfyear, net of tax
Total comprehensive loss for the half-year
Transactions with owners in their capacity as
owners:
Vesting of Tranche A Performance Rights
(note 17)
Share-based payments (note 17)
Balance at 31 December 2024
Options
reserve
$
Accumulated
losses
Total equity
$
$
The above condensed statement of changes in equity should be read in conjunction with the accompanying notes
8
Resonance Health Limited
Condensed consolidated statement of cash flows
For the half-year ended 31 December 2024
Note
Consolidated
31 Dec 2024 31 Dec 2023
$
$
Cash flows from operating activities
Receipts from customers
Payments to suppliers and employees
8,287,630
(7,213,227)
3,186,134
(3,465,938)
Interest received
Grants received
Interest and other Finance Costs Paid
1,074,403
33,605
25,500
(132,190)
(279,804)
76,419
59,860
-
Net cash provided by/(used in) operating activities
1,001,318
(143,525)
(3,914,836)
(105,935)
(83,719)
(210,278)
(62,573)
(4,104,490)
(272,851)
Repayment of lease liabilities
(133,659)
(58,480)
Repayment of borrowings
(160,000)
-
Payments for cash-backed guarantees
(11,502)
(19,824)
Net cash used in financing activities
(305,161)
(78,304)
Net decrease in cash and cash equivalents
Cash and cash equivalents at the beginning of the financial half-year
Effects of exchange rate changes on cash and cash equivalents
(3,408,333)
6,854,820
66,228
(494,680)
6,361,621
31,080
Cash and cash equivalents at the end of the financial half-year
3,512,715
5,898,021
Cash flows from investing activities
Cash paid to acquire TrialsWest (deferred consideration)
Payments for property, plant and equipment
Payments for intangibles
18
8
Net cash used in investing activities
Cash flows from financing activities
The above condensed statement of cash flows should be read in conjunction with the accompanying notes
9
Resonance Health Limited
Notes to the condensed financial statements
31 December 2024
Note 1. General information
The financial statements cover Resonance Health Limited as a Group consisting of Resonance Health Limited and the
entities it controlled at the end of, or during, the half-year. The financial statements are presented in Australian dollars,
which is Resonance Health Limited's functional and presentation currency.
Resonance Health Limited is a listed public company limited by shares, incorporated and domiciled in Australia. Its
registered office and principal place of business is:
141 Burswood Road
BURSWOOD WA 6100
T: +61 8 9286 5300
F: +61 8 9286 5399
A description of the nature of the Group's operations and its principal activities are included in the Directors' report, which
is not part of the financial statements.
The financial statements were authorised for issue, in accordance with a resolution of Directors, on 27 February 2025.
Note 2. Significant accounting policies
These general-purpose financial statements for the interim half-year reporting period ended 31 December 2024 have
been prepared in accordance with Australian Accounting Standard AASB 134 'Interim Financial Reporting' and the
Corporations Act 2001, as appropriate for for-profit oriented entities. Compliance with AASB 134 ensures compliance with
International Financial Reporting Standard IAS 34 'Interim Financial Reporting'.
These general-purpose financial statements do not include all the notes of the type normally included in annual financial
statements. Accordingly, these financial statements are to be read in conjunction with the annual report for the year
ended 30 June 2024 and any public announcements made by the Company during the interim reporting period in
accordance with the continuous disclosure requirements of the Corporations Act 2001.
The principal accounting policies adopted are consistent with those of the previous financial year and corresponding
interim reporting period, unless otherwise stated.
New or amended Accounting Standards and Interpretations adopted
The Group has adopted all of the new or amended Accounting Standards and Interpretations issued by the Australian
Accounting Standards Board ('AASB') that are mandatory for the current reporting period. These had no material impact
on the group.
Any new or amended Accounting Standards or Interpretations that are not yet mandatory have not been early adopted.
These are not likely to have material effect on the group.
Going concern
The financial report has been prepared on the going concern basis, which contemplates continuity of normal business
activities and the realisation of assets and settlement of liabilities in the ordinary course of business.
Note 3. Operating segments
Identification of reportable operating segments
The chief operating decision maker is considered to be the Company’s Board of Directors. The Group’s operating segments
are determined by differences in the type of activities performed. The financial results of the Group’s operating segments
are reviewed by the Board of Directors on a monthly basis.
10
Resonance Health Limited
Notes to the condensed financial statements
31 December 2024
Note 3. Operating segments (continued)
Business Segments
The following table presents revenue and profit/(loss) information and certain asset and liability information regarding
business segments for the half-year ended 31 December 2024.
Consolidated - 31 Dec 2024
Revenue
Sales to external customers
Total segment revenue
Reconciliation of segment
revenue to Group revenue:
Intersegment
elimination
Total Group Revenue
Services
$
Research and
development Corporate
$
$
CRO
$
TrialsWest
$
Total
$
2,562,864
2,562,864
-
1,718,212
1,718,212
1,526,372
1,526,372
5,807,448
5,807,448
-
(596,971)
5,210,477
Total revenue
2,562,864
Other income
Other expenses
(1,593,828)
(Loss)/profit before income tax
benefit
969,036
Income tax benefit
Loss after income tax benefit
58,164
(630,570) (1,996,085)
1,718,212
(2,075,264)
1,526,372
(1,079,343)
5,807,448
58,164
(7,375,090)
(630,570) (1,937,921)
(357,052)
447,029
(1,509,478)
473,286
(1,036,192)
Assets
Segment assets
Total assets
1,050,161
1,050,161
2,571,736 5,866,742
2,571,736 5,866,742
690,444
690,444
7,759,259
7,759,259
17,938,342
17,938,342
Liabilities
Segment liabilities
Total liabilities
1,360,364
1,360,364
16,338 3,343,528
16,338 3,343,528
2,515,428
2,515,428
664,753
664,753
7,900,411
7,900,411
11
Resonance Health Limited
Notes to the condensed financial statements
31 December 2024
Note 3. Operating segments (continued)
Consolidated - 31 Dec 2023
Services
$
Research and
development Corporate
$
$
Revenue
Sales to external customers
Total revenue
2,210,856
2,210,856
-
Other
segments
$
CRO
$
-
1,054,704
1,054,704
-
3,265,560
3,265,560
2,210,856
(1,516,749)
123,843
(481,909) (1,758,250)
1,054,704
(190,047)
-
3,265,560
123,843
(3,946,955)
694,107
694,107
(481,909) (1,634,407)
(481,909) (1,634,407)
864,657
864,657
-
(557,552)
(557,552)
Assets
Segment assets
Total assets
1,263,489
1,263,489
2,641,841 7,015,615
2,641,841 7,015,615
-
-
10,920,945
10,920,945
Liabilities
Segment liabilities
Total liabilities
947,156
947,156
-
10,870
10,870
-
1,083,416
1,083,416
Total revenue
Other income
Other expenses
(Loss)/profit before income tax
benefit
Income tax benefit
Loss after income tax benefit
Total
$
Consolidated – 31 Dec 2023
125,390
125,390
The Group derived 32% of its external customer sales revenue from one major customer. For the period to December
2023, the Group derived 32% of its external customer sales revenue from one major customer and 10% of its external
customer sales revenue from a second major customer.
Geographical Segments
The Group earns revenue in three significant geographical regions, countries are grouped in the regions of Asia/Pacific,
North America and Europe-Middle East-Africa (EMEA).
All non-current assets are located in Australia being the Asia/Pacific region, applicable disclosure information is disclosed
in Business Segment assets and no additional disclosure is made.
Consolidated
31 Dec 2024 31 Dec 2023
$
$
Asia/Pacific
North America
EMEA
2,872,246
1,416,078
922,153
1,180,892
1,285,710
798,958
Total sales to external customers
5,210,477
3,265,560
Note 4. Revenue
Disaggregation of revenue
The Group derives its revenue from the services at a point in time and over time in the following major categories. This is
consistent with the revenue information that is disclosed for each reportable segment:
12
Resonance Health Limited
Notes to the condensed financial statements
31 December 2024
Note 4. Revenue (continued)
Consolidated
31 Dec 2024 31 Dec 2023
$
$
Revenue from contracts with customers
At a point in time:
Commercial revenue
Clinical trials
Other studies
Over time:
Clinical trials
1,574,238
1,278,182
226,486
1,362,498
1,467,983
115,620
2,131,571
319,459
Revenue
5,210,477
3,265,560
Reconciliation of revenue from contracts with customers with the amounts disclosed in segment information
Consolidated
31 Dec 2024 31 Dec 2023
$
$
Segment revenue
Adjustments and eliminations
5,807,448
(596,971)
3,265,560
-
Total revenue from contracts with customers
5,210,477
3,265,560
Note 5. Other income
Consolidated
31 Dec 2024 31 Dec 2023
$
$
Subsidies and grants
Interest revenue
25,500
32,664
59,860
63,983
Other income
58,164
123,843
Note 6. Property, plant and equipment
Consolidated
31 Dec 2024 30 Jun 2024
$
$
Non-current assets
Plant and equipment - at cost
Less: Accumulated depreciation
13
996,971
(446,512)
889,631
(366,840)
550,459
522,791
Resonance Health Limited
Notes to the condensed financial statements
31 December 2024
Note 6. Property, plant and equipment (continued)
Reconciliations
Reconciliations of the written down values at the beginning and end of the current and previous financial half-year are set
out below:
Plant and
equipment
$
Consolidated
Balance at 1 July 2023
Additions
PPE acquired - Acquisition of TrialsWest (Refer Note 18)
Depreciation expense
385,106
229,261
27,481
(119,057)
Balance at 30 Jun 2024
Additions
PPE adjustment – Acquisition of TrialsWest (Refer Note 18)
Depreciation expense
522,791
109,501
(2,180)
(79,653)
Balance at 31 December 2024
550,459
Note 7. Right-of-use assets
Consolidated
31 Dec 2024 30 Jun 2024
$
$
Non-current assets
Land and buildings - right-of-use
Less: Accumulated depreciation
948,970
(421,821)
778,105
(286,057)
527,149
492,048
The Group has six premises leases.
Reconciliations
Reconciliations of the written down values at the beginning and end of the current and previous financial half-year are set
out below:
Land and
buildings
$
Consolidated
Balance at 1 July 2023
Additions
ROU acquired - Acquisition of TrialsWest (Refer Note 18)
Depreciation expense
244,494
327,502
43,721
(123,669)
Balance at 30 June 2024
492,048
Additions
Depreciation expense
170,866
(135,765)
Balance at 31 December 2024
527,149
14
Resonance Health Limited
Notes to the condensed financial statements
31 December 2024
Note 8. Intangibles
Consolidated
31 Dec 2024 30 Jun 2024
$
$
Non-current assets
Development - at cost
Less: Accumulated amortisation
4,572,004
(2,000,268)
4,488,286
(1,882,102)
Goodwill (Refer Note 18)
5,270,147
7,257,606
Other Intangible Assets (Refer Note 18)
Less: Accumulated amortisation
2,007,000
(155,823)
-
9,693,060
9,863,790
Reconciliations
Reconciliations of the written down values at the beginning and end of the current and previous financial periods are set
out below:
Consolidated
$
Balance at 1 July 2023
Additions
Intangible Assets on acquisition of TrialsWest (Refer Note 18)
Amortisation expense
2,713,349
148,055
7,257,606
(255,220)
Balance at 30 June 2024
9,863,790
Additions
Intangible Adjustment on acquisition of TrialsWest (Refer Note 18)
Amortisation expense
83,719
19,541
(273,990)
Balance at 31 December 2024
9,693,060
Development expenditure relates to costs incurred in developing MRI image analysis tools for the diagnosis and clinical
management of human disease.
During the current financial year this development has related primarily to automation of organ fat and iron assessment
tools, further refinement of FerriScan® and the next stage of development of an MRI based liver fibrosis tool.
The recoupment of development expenditure is dependent on the successful development and commercialisation or sale
of the technology developed. The Directors are required to assess at each reporting date whether there is an indication
that an asset may be impaired. If any such indication exists an estimate is made of the asset’s recoverable amount.
Impairment tests are also required for intangible assets not yet ready for use regardless of the existence of indicators of
impairment. Where the asset’s carrying value exceeds the estimated recoverable amount a provision for impairment is
recognised.
In making this assessment the Directors had regard to the size of the liver iron, liver fibrosis and liver fat markets,
competing products, experience gained with the FerriScan® technology, the likely period over which these revenues are
expected to be generated and the likelihood of any technological obsolescence.
Based upon this assessment, no impairment indicators were determined to be present at 31 December 2024. A full
impairment assessment including intangible assets not yet available for use will be conducted at 30 June 2025 in
accordance with AASB 136.
15
Resonance Health Limited
Notes to the condensed financial statements
31 December 2024
Note 9. Lease liabilities
The Group leases only premises.
Consolidated
31 Dec 2024 30 Jun 2024
$
$
Current liabilities
Lease liability
183,314
171,630
Non-current liabilities
Lease liability
400,975
351,439
584,289
523,069
Note 10. Other Liabilities
This balance represents amounts received from contracts with customers where the performance obligations for
recognising revenue have yet to be met at balance date.
Consolidated
31 Dec 2024 30 Jun 2024
$
$
Current liabilities
Unearned income
2,050,731
11,240
Consolidated
30 Jun 2024 31 Dec 2024
Shares
$
30 Jun 2024
$
Note 11. Issued capital
31 Dec 2024
Shares
Ordinary shares - fully paid
459,616,138 446,892,928
74,452,640
74,166,888
On 6 November 2024, 5,454,977 Tranche B Performance Rights vested and were converted into shares. As a result, the
fair value at date of issue was transferred from reserves to issued capital totalling $285,752.
On 6 November 2024, 7,268,233 Loan Shares were provided to the CEO and CFO per which they repay the Company
$0.0583 for each loan share issued to them, within 5 years from the issue date. Loan shares not repaid by that date will
be forfeited. Refer to note 17 for further details.
Ordinary shares
Ordinary shares entitle the holder to participate in dividends and the proceeds on the winding up of the Company in
proportion to the number of and amounts paid on the shares held. The fully paid ordinary shares have no par value and
the Company does not have a limited amount of authorised capital.
On a show of hands every member present at a meeting in person or by proxy shall have one vote and upon a poll each
share shall have one vote.
Share buy-back
There is no current on-market share buy-back.
16
Resonance Health Limited
Notes to the condensed financial statements
31 December 2024
Note 12. Dividends
There were no dividends paid, recommended or declared during the current or previous financial half-year.
Note 13. Financial instruments
The methods and valuation techniques used for the purpose of measuring fair value are unchanged compared to the
previous reporting period.
The carrying amounts of current receivables and current payables are considered to be a reasonable approximation of
their fair value.
Note 14. Contingent liabilities
There are no contingent liabilities at balance date.
Note 15. Related party transactions
Parent entity
Resonance Health Limited is the parent entity.
Transactions with related parties
The following transactions occurred with related parties:
Consolidated
31 Dec 2024 31 Dec 2023
$
$
Sale of goods and services:
Services provided to Perth Radiological Clinic *
1,395
1,357
Payment for goods and services:
Services provided by Perth Radiological Clinic *
-
545
*
Dr Martin Blake is a shareholder and consulting Radiologist of Perth Radiological Clinic.
Receivable from and payable to related parties
The following balances are outstanding at the reporting date in relation to transactions with related parties:
Consolidated
31 Dec 2024 30 Jun 2024
$
$
Current receivables:
Trade receivables from Perth Radiological Clinic
307
307
Loans to/from related parti
Share your feedback
Discover